May 27, 2021
Astellas Pharma unveiled its five-year business plan on May 26, aiming to rack up a compound average growth rate (CAGR) of 8% through FY2025 and derive 1.2 trillion yen from its flagship cancer drug Xtandi (enzalutamide) and six strategic products...read more